Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic
Leukemia
- Kazunori Ohnishi, MD;
- Hitoshi Yoshida, MD;
- Kazuyuki Shigeno, MD;
- Satoki Nakamura, MD;
- Shinya Fujisawa, MD;
- Kensuke Naito, MD;
- Kaori Shinjo, MD;
- Yota Fujita, MD;
- Hirotaka Matsui, MD;
- Akihiro Takeshita, MD;
- Shiho Sugiyama, MD;
- Hiroshi Satoh, MD;
- Hajime Terada, MD; and
- Ryuzo Ohno, MD
-
From Hamamatsu University School of Medicine, Hamamatsu, and Aichi Cancer Center Hospital, Nagoya, Japan.
-
Figure. Patient 1 received arsenic trioxide until day 43. Seven successive ventricular premature contractions developed on
day 25, and mexiletine HCl was administered from day 28 to 148. VT = ventricular tachycardia. Electrocardiographic tracing and QT intervals in patient 1 during arsenic trioxide therapy.
- Copyright ©2004 by the American College of Physicians
-
Ann Intern Med
December 5, 2000
vol. 133
no. 11
881-885
RSS Feeds
Figure. Patient 1 received arsenic trioxide until day 43. Seven successive ventricular premature contractions developed on day 25, and mexiletine HCl was administered from day 28 to 148. VT = ventricular tachycardia. Electrocardiographic tracing and QT intervals in patient 1 during arsenic trioxide therapy.
